Analyst Ratings For NASDAQ:APLS – Apellis Pharmaceuticals (NASDAQ:APLS)
Today, NASDAQ:APLS – Apellis Pharmaceuticals (NASDAQ:APLS) stock was downgraded by B. Riley from Buy to Neutral with a price target of $27.00.
Some recent analyst ratings include
- 4/12/2018-B. Riley was Downgraded by analysts at B. Riley from a “Buy ” rating to a ” Neutral” rating. They now have a $27.00 price target on the stock.
- 12/4/2017-Evercore ISI initiated coverage with a Outperform rating.
- 12/4/2017-Citigroup initiated coverage with a Buy rating.
- On 11/13/2017 Global Strategic Fund I Venbio, Major Shareholder, bought 127,515 with an average share price of $14.00 per share and the total transaction amounting to $1,785,210.00.
Recent Trading Activity for NASDAQ:APLS – Apellis Pharmaceuticals (NASDAQ:APLS)
Shares of NASDAQ:APLS – Apellis Pharmaceuticals closed the previous trading session at 26.08 down -1.19 4.38% with 25.010000228881836 shares trading hands.
